MedTrace Logo

Post-market Clinical Investigation of the Angio-Seal™ VIP VCD (ANGIO-SEAL CLOSE)

NCT05335525 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 230

Last updated 2023-04-20

No results posted yet for this study

Summary

The present post-market surveillance study aims to evaluate the safety and effectiveness of the Angio-SealTM VIP VCD in patients undergoing endovascular procedures via femoral access in real-world setting.

Conditions

  • Vascular Closure
  • Endovascular Procedure
  • Hemostasis
  • Peripheral Vascular Disease
  • Femoral Artery

Interventions

DEVICE

Closure of the femoral arterial puncture site

Patient will undergo a diagnostic or interventional endovascular procedure, compatible with the use of Angio-Seal™ VIP VCD.

Sponsors & Collaborators

  • Terumo Medical Corporation

    collaborator INDUSTRY

  • Terumo Europe N.V.

    lead INDUSTRY

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-09-30
Primary Completion
2023-05-31
Completion
2023-05-31

Countries

  • France
  • Germany
  • Netherlands

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05335525 on ClinicalTrials.gov